Published in Mol Neurodegener on August 30, 2010
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci (2011) 2.84
Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol (2013) 1.32
Cellular model of TAR DNA-binding protein 43 (TDP-43) aggregation based on its C-terminal Gln/Asn-rich region. J Biol Chem (2012) 1.08
RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci (2012) 1.07
Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci (2014) 1.06
Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS One (2011) 1.00
Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol (2011) 0.97
The structural integrity of TDP-43 N-terminus is required for efficient aggregate entrapment and consequent loss of protein function. Prion (2015) 0.97
Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol (2015) 0.95
CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol (2013) 0.94
Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. Mol Ther (2013) 0.92
RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. Wiley Interdiscip Rev RNA (2011) 0.90
Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation. Mol Neurodegener (2010) 0.90
Cdc37/Hsp90 protein complex disruption triggers an autophagic clearance cascade for TDP-43 protein. J Biol Chem (2012) 0.90
Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. Proc Natl Acad Sci U S A (2014) 0.89
UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. J Biol Chem (2014) 0.88
TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. J Alzheimers Dis (2013) 0.85
Inhibition of TDP-43 aggregation by nucleic acid binding. PLoS One (2013) 0.83
Legal but lethal: functional protein aggregation at the verge of toxicity. Front Cell Neurosci (2015) 0.81
Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. J Alzheimers Dis Parkinsonism (2013) 0.81
TDP-43/FUS in motor neuron disease: Complexity and challenges. Prog Neurobiol (2016) 0.79
Cytoplasmic translocation, aggregation, and cleavage of TDP-43 by enteroviral proteases modulate viral pathogenesis. Cell Death Differ (2015) 0.76
Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Continuum. Front Mol Neurosci (2017) 0.76
Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases. Front Mol Neurosci (2017) 0.75
The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathol (2016) 0.75
Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities? Front Mol Neurosci (2017) 0.75
PABPN1 suppresses TDP-43 toxicity in ALS disease models. Hum Mol Genet (2015) 0.75
A 43-kDa TDP-43 species is present in aggregates associated with frontotemporal lobar degeneration. PLoS One (2013) 0.75
Nutrient deprivation induces α-synuclein aggregation through endoplasmic reticulum stress response and SREBP2 pathway. Front Aging Neurosci (2014) 0.75
The Myoblast C2C12 Transfected with Mutant Valosin-Containing Protein Exhibits Delayed Stress Granule Resolution on Oxidative Stress. Am J Pathol (2016) 0.75
The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. Front Neurosci (2017) 0.75
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J (2000) 41.48
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun (2006) 10.69
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell (2008) 3.64
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol (2008) 3.13
Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem (2009) 2.60
Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron (2003) 2.39
Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Hum Mol Genet (2009) 2.23
Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol (2006) 1.93
Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem (2005) 1.88
Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem (2009) 1.76
HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J (2006) 1.75
The role of tau in neurodegeneration. Mol Neurodegener (2009) 1.54
Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem (2009) 1.53
Degradation of TDP-43 and its pathogenic form by autophagy and the ubiquitin-proteasome system. Neurosci Lett (2009) 1.53
Synergistic effect between proteasome and autophagosome in the clearance of polyubiquitinated TDP-43. J Neurosci Res (2010) 1.26
Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells. J Neurochem (2004) 1.01
Assembly of filamentous tau aggregates in human neuronal cells. J Alzheimers Dis (2004) 0.90
Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol (2006) 0.89
Retracted Cytomegalovirus promoter up-regulation is the major cause of increased protein levels of unstable reporter proteins after treatment of living cells with proteasome inhibitors. J Biol Chem (2009) 0.89
Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron (2013) 3.25
Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med (2013) 2.89
Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci (2008) 2.79
Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci (2010) 2.60
Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. PLoS One (2010) 2.49
Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29
Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol (2013) 2.26
Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol (2010) 2.20
Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci (2006) 1.98
Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol (2013) 1.95
TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90
HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J (2006) 1.75
C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A (2009) 1.64
Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61
Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol (2003) 1.58
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem (2002) 1.57
Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet (2010) 1.56
Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci (2008) 1.54
The role of tau in neurodegeneration. Mol Neurodegener (2009) 1.54
Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol (2014) 1.54
Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol (2013) 1.52
TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol (2014) 1.47
Disease-related modifications in tau affect the interaction between Fyn and Tau. J Biol Chem (2005) 1.45
Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord (2007) 1.44
Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol (2013) 1.41
Molecular pathogenesis of Parkinson disease. Arch Neurol (2005) 1.36
Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol (2013) 1.36
Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol (2014) 1.35
Hippocampal sclerosis dementia with tauopathy. Brain Pathol (2003) 1.34
Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol (2003) 1.34
Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron (2003) 1.33
Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. Curr Alzheimer Res (2005) 1.33
Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol Commun (2013) 1.32
Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur J Neurosci (2007) 1.31
An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst (2012) 1.29
Brain CHIP: removing the culprits in neurodegenerative disease. Trends Mol Med (2006) 1.27
Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener (2011) 1.20
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Progranulin regulates neuronal outgrowth independent of sortilin. Mol Neurodegener (2012) 1.14
Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau. J Neurocytol (2006) 1.11
The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum Mol Genet (2013) 1.11
Proteasome inhibition and Parkinson's disease modeling. Ann Neurol (2006) 1.10
Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Res Mol Brain Res (2005) 1.08
Disruption of protein quality control in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.07
Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc Natl Acad Sci U S A (2012) 1.07
RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci (2012) 1.07
Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS One (2010) 1.06
Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol (2005) 1.05
MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer (2013) 1.05
Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet (2013) 1.05
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol (2002) 1.04
Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med (2005) 1.04
A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim Biophys Acta (2009) 1.02
Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol (2003) 1.02
The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet (2013) 1.02
Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet (2012) 1.00
ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J Neurosci (2014) 1.00
Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis (2013) 0.99
Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathol (2014) 0.98
Neuronal sensitivity to TDP-43 overexpression is dependent on timing of induction. Acta Neuropathol (2012) 0.97
TDP-1/TDP-43 regulates stress signaling and age-dependent proteotoxicity in Caenorhabditis elegans. PLoS Genet (2012) 0.97
The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. PLoS One (2009) 0.97
Current strategies for the treatment of Alzheimer's disease and other tauopathies. Expert Opin Ther Targets (2006) 0.95
TDP-43 in neurodegenerative disorders. Expert Opin Biol Ther (2008) 0.94
Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency. Hum Mol Genet (2013) 0.93
Effect of family history of cancers and environmental factors on risk of nasopharyngeal carcinoma in Guangdong, China. Cancer Epidemiol (2010) 0.93
Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener (2006) 0.92
Selective forelimb impairment in rats expressing a pathological TDP-43 25 kDa C-terminal fragment to mimic amyotrophic lateral sclerosis. Mol Ther (2013) 0.92